International conference abstracts & presentations

2024

HAI 2024
  • Fajardo-Valdez A, Yakoub Y, Javanray M, St-Onge F, Gallego Rudolf J, Qiu T, Ourry V, Remz J, Soucy J-P, Ashton NJ, Zetterberg H, Blennow K, Poirier J, Breitner JCS, Villeneuve S. (2024) Longitudinal change of cerebral amyloid and tau and its association with plasma biomarkers in preclinical Alzheimer’s disease. Human Amyloid Imaging conference. Miami, USA. Oral Presentation
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2024) Optimizing the detection of whole-brain tau-related cognitive decline in mild cognitive impairment. Human Amyloid Imaging conference. Miami, USA. Oral Presentation
  • Gallego Rudolf J, Wiesman A, Baillet S, Villeneuve S. (2024) Neurophysiological changes related to amyloid and tau pathology are associated with longitudinal cognition and Mild Cognitive Impairment progression. Human Amyloid Imaging conference. Miami, USA.
  • Ourry V, St-Onge F, Mohammediyan B, Yakoub Y, Soucy J-P, Poirier J, Breitner JCS, Villeneuve S. (2024) Aβ and tau associations with sex and affected parent’s sex in preclinical Alzheimer’s disease. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Yakoub Y, Ashton NJ, Karikari T, Strikwerda-Brown C, St-Onge F, Ourry V, Schöll M, Geddes MR, Ducharme S, Rosa-Neto P, Soucy J-P, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2024) The role of biofluid markers in predicting near-term cognitive impairment. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Yakoub Y, St-Onge F, Fajardo-Valdez A, Mohammediyan B, Dery C, Sylvain E, Tremblay-Mercier J, Remz J, Gonneaud J, Vogel J, Soucy J-P, Pichet Binette A, Villleneuve S, PREVENT-AD Research Group. (2024) A-T+ PET participants in preclinical AD: clinical progression and concordance with fluid biomarkers. Human Amyloid Imaging conference. Miami, USA. [PDF]

2023

OHBM 2023
  • Gallego Rudolf J, Wiesman AI, Pichet Binette A, Baillet S, Villeneuve S, PREVENT-AD Research Group. (2023) Hyper- and hypoactive neurophysiological changes related to early Alzheimer’s Disease proteinopathy. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada.
  • Javanray M, Bellec P, Misic B, Villeneuve S, for the PREVENT-AD Research Group. (2023) Brain functional flexibility and its link to Alzheimer’s pathology at the preclinical stage. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
  • Mohammediyan B, Baril A-A, St-Onge F, Ourry V, Carrier J, Soucy J-P, Breitner JCS, Poirier J, Villeneuve S, for the PREVENT-AD Research Group. (2023) Associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adults. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
  • Qiu T, Liu Z-Q, Rheault F, Valcourt-Caron A, Legarreta JH, St-Onge F, Strikwerda-Brown C, Pichet Binette A, Spreng RN, Descoteaux M, Villeneuve S, for the PREVENT-AD Research Group. (2023) The role of white matter in cognitive resilience to pathology in individuals at risk of AD. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
  • Qiu T, Rheault F, Soucy J-P, Spreng RN, Pichet Binette A, Descoteaux M, Villeneuve S, for the PREVENT-AD Research Group. (2023) Amyloid and tau pathology are associated with white matter properties in cognitively unimpaired older adults at risk of AD dementia. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2023) Capturing the spatial extent of tau pathology in the Alzheimer’s Disease spectrum. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
  • Yakoub Y, Ashton N, Strikwerda-Brown C, Montoliu-Gaya L, Karikari T, Kac P, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer P-F, St-Onge F, Schöll M, Breitner J, Zetterberg H, Blennow K, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2023) Longitudinal blood biomarker trajectories in preclinical Alzheimer’s Disease. 29th Annual Meeting of the Organization for Human Brain Mapping. Montreal, Canada. [PDF]
AAIC 2023
  • Gallego Rudolf J, Wiesman AI, Baillet S, Villeneuve S, PREVENT-AD Research Group. (2023) Neurophysiological activity linked to Alzheimer’s disease pathology relates to MCI progression. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. Oral Presentation [PPTX]
  • Gallego Rudolf J, Wiesman AI, Baillet S, Villeneuve S, PREVENT-AD Research Group. (2023) Neurophysiological activity linked to Alzheimer’s disease pathology relates to longitudinal cognition and progression to mild cognitive impairment. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • Mohammediyan B, Baril A-A, St-Onge F, Ourry V, Carrier J, Soucy J-P, Breitner JCS, Poirier J, Villeneuve S, for the PREVENT-AD Research Group. (2023) Sleep quality and day-to-day variability: Relation to Alzheimer’s pathology in cognitively unimpaired older adults at-risk of AD dementia. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • Ourry V, St-Onge F, Mohammediyan B, Yakoub Y, Soucy J-P, Poirier J, Breitner JCS, Villeneuve S, for the PREVENT-AD Research Group. (2023) Sex and family history differences in Aβ and tau vulnerability in preclinical Alzheimer’s disease. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • Qiu T, Rheault F, Soucy J-P, Spreng RN, Pichet Binette A, Descoteaux M, Villeneuve S, for the PREVENT-AD Research Group. (2023) Amyloid and tau pathology are associated with white matter properties in cognitively unimpaired older adults at risk of AD dementia. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2023) Domain-specific cognitive decline associates with differential regional tau burden in the Alzheimer’s disease spectrum. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2023) Tracing the spatial extent of cortical tau over time in Alzheimer’s disease. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2023) Tracing the spatial extent of cortical tau over time in Alzheimer’s disease. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. Oral Presentation [PDF]
  • Yakoub Y, Ashton NJ, Karikari TK, Montoliu-Gaya L, Schöll M, Spreng RN, Rosa-Neto P, Soucy J-P, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S. (2023) The role of biofluid markers in predicting near-term cognitive impairment. Alzheimer’s Association International Conference. Amsterdam, The Netherlands. [PDF]
HAI 2023
  • Mohammediyan B, Baril A-A, St-Onge F, Ourry V, Carrier J, Soucy J-P, Breitner JCS, Poirier J, Villeneuve S. (2023) Longitudinal bidirectional associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adults. Human Amyloid Imaging conference. Miami, USA. Oral Presentation [PDF]
  • Ourry V, St-Onge F, Mohammediyan B, Yakoub Y, Soucy J-P, Poirier J, Breitner JCS, Villeneuve S. (2023) Sex differences in Aβ and tau vulnerability in preclinical Alzheimer’s disease. Human Amyloid Imaging conference. Miami, USA. [PDF]

2022

  • Strikwerda-Brown C, St-Onge F, Yakoub Y, Ozlen H, Pichet Binette A, Breitner JCS, Villeneuve S. (2022) Associations between psychological factors, resistance and resilience to AD pathology, and grey matter volume in cognitively unimpaired older adults. Alzheimer’s Association International Conference. San Diego, USA. Oral Presentation [PPTX]
  • Strikwerda-Brown C, Hobbs D.A., Gonneaud J, St-Onge F, Pichet Binette A, Ozlen H, Provost K, Soucy J-P, Buckley R.F, Benzinger T L.S, Morris J.C, Villemagne V.L, Doré V, Sperling R.A, Johnson K.A, Rowe C.C, Gordon B.A, Poirier J, Breitner JCS, Villeneuve S. (2022) Elevated Aβ and tau PET signal predict near-term progression to mild cognitive impairment in cognitively unimpaired older adults. Alzheimer’s Association International Conference. San Diego, USA. Oral Presentation [PPTX] [PDF]
  • Gallego Rudolf J, Wiesman A.I, Pichet Binette A, Villeneuve S, Baillet S. (2022) Neurophysiological markers of early Alzheimer’s disease proteinopathy in the human brain. Alzheimer’s Association International Conference. San Diego, USA. [PDF]
  • Yakoub Y, Ashton N.J, Strikwerda-Brown C, Montoliu-Gaya L, Karikari T.K, Kac P.R, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer P-F, St-Onge F, Schöll M, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S. (2022) Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease. Alzheimer’s Association International Conference. San Diego, USA. [PDF]
  • Qiu T, Liu Z-Q, Strikwerda-Brown C, St-Onge F, Pichet Binette A, Descoteaux M, Villeneuve S. (2022) Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia. Alzheimer’s Association International Conference. San Diego, USA. [PDF]

2021

  • Strikwerda-Brown C, Ozlen H, Pichet Binette A, Chapleau M, Villeneuve S. (2021) Mindfulness is associated with amyloid, tau and cognition in preclinical AD. Alzheimer’s Association International Conference. Denver, USA. Oral Presentation
  • Chapleau M, Pichet Binette A, Villeneuve S, Alzheimer’s Disease Neuroimaging Initiative. (2021) Characterizing flortaucipir tau-PET deposition patterns across the Alzheimer’s disease spectrum – A comparison between regional and whole-brain approaches. Alzheimer’s Association International Conference. Denver, USA. Oral Presentation [PPTX]

2020

  • Meyer P-F, Ashton N, Karikari T, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Pannee J, Simrén J, Labonté A, Schöll M, Rosa-Neto P, Breitner JCS, Poirier J, Zetterberg H, Blennow K, Villeneuve S; for the PREVENT-AD Research Group. (2020) Plasma biomarkers associate with amyloid and tau PET binding in cognitively unimpaired older adults with a parental history of AD. Human Amyloid Imaging conference. Miami, USA. Oral Presentation [PDF]
  • Ozlen H, Pichet Binette A, Köbe T, Meyer P-F, Villeneuve S, PREVENT-AD Research Group. (2020) Widespread amyloid is necessary to detect tau-PET signal beyond the entorhinal cortex and cognitive decline. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Meyer P-F, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S; for the Alzheimer’s Disease Neuroimaging Initiative. (2020) Cerebrospinal fluid and PET measures of tau pathology may indicate different stages of AD pathological progression. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Pichet Binette A, Theaud G, Rheault F, Gonneaud J, Roy M, Poirier J, Descoteaux M, Villeneuve S, PREVENT-AD Research Group. (2020) Amyloid and tau PET burden are associated with white matter bundle abnormalities in asymptomatic individuals at risk of Alzheimer’s disease. Human Amyloid Imaging conference. Miami, USA. [PDF]

2019

  • Meyer P-F, Pichet Binette A, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2019) Cerebrospinal fluid and PET measures of tau pathology reflect different states of AD pathophysiological progression. Alzheimer’s Association International Pre-Conference. Los Angeles, USA. [PDF]
  • Pichet Binette A, Gonneaud J, Poirier J, Breitner JC, Villeneuve S, Vachon-Presseau E, ADNI, PREVENT-AD Research Group. (2019) Grey matter volume & whole-brain pattern organization across lifespan and Alzheimer’s disease. Organization for Human Brain Mapping. Rome, Italy.
  • Guay S, Pichet Binette A, PREVENT-AD Research Group, Villeneuve S, de Beaumont L. (2019) Athletes with sports concussions show distinct tau-PET deposition relative to aging nonathletes. Organization for Human Brain Mapping. Rome, Italy.
  • Gonneaud J, Vachon-Presseau E, Baria A, Pichet Binette A, Benzinger T, Morris J, Bateman R, Breitner J, Poirier J, Villeneuve S, The DIAN Study Group, PREVENT-AD Research Group. (2019) Prediction of brain age using resting-state functional connectivity suggests accelerated aging in the preclinical phase of autosomal dominant Alzheimer’s disease, irrespectively of amyloid pathology. Human Amyloid Imaging. Miami, USA. [PDF]
  • Köbe T, Gonneaud J, Pichet Binette A, Meyer P-F, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; for the PREVENT-AD Research Group. (2019) Vascular medical treatment influences the association between vascular burden and amyloid pathology in middle-to-late-aged cognitively healthy individuals at-risk for Alzheimer’s disease. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Rosa-Neto P, Breitner JCS, Poirier J, & Villeneuve S for the PREVENT-AD Research Group. (2019) Early increase in tau-PET signal is associated with changes in amyloid, CSF p-tau, and cognition in cognitively normal adults. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Pichet Binette A, Gonneaud J, Villeneuve S, Alzheimer’s Disease Neuroimaging Initiative. (2019) [18F]AV1451 deposition pattern across the Alzheimer’s disease spectrum – Characterization at the individual level. Human Amyloid Imaging conference. Miami, USA. [PDF]
  • Pichet Binette A, Gonneaud J, Ozlen H, Bedetti C, Morris JC, Bateman RJ, Benzinger TLS, Poirier J, Breitner JCS, Villeneuve S, the DIAN Study Group, PREVENT-AD Research Group. (2019) Associations between behavioral factors and Alzheimer’s pathology: Findings from cognitively normal older adults at risk of AD and presymptomatic ADAD mutation carriers. Human Amyloid Imaging conference. Miami, USA. [PDF]

2018

  • Gonneaud J*, Vachon-Presseau E*, Baria A, Pichet Binette A, Benzinger T, Morris J, Bateman R, Breitner J, Poirier J, Villeneuve S, for the PREVENT-AD Research Group. (2018) The preclinical phase of autosomal dominant Alzheimer’s disease is characterized by accelerated brain aging. Montreal Artificial Intelligence & Neuroscience (MAIN) Conference. Montreal, Canada. * Prize [PDF]
  • Gonneaud J, Vachon-Presseau E, Baria A, Pichet Binette A, Benzinger T, Morris J, Bateman R, Breitner J, Poirier J, Villeneuve S, The DIAN Study Group, PREVENT-AD Research Group. (2018) Prediction of brain age using resting-state functional connectivity reveals accelerated aging in the preclinical phase of autosomal dominant Alzheimer’s disease, irrespectively of amyloid pathology. Biennial Conference on Resting-State and Brain Connectivity. Montreal, Canada. [PDF]
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Poirier J, Rosa-Neto P, Breitner JC, Villeneuve S for the PREVENT-AD Research Group. (2018) Early increase in tau-PET signal is associated with Aβ burden, CSF p-tau levels and cognition in cognitively normal late-middle-aged adults. Alzheimer’s Association International Conference. Chicago, USA. Oral Presentation [PDF]
  • Gonneaud J*, Bedetti C, Pichet Binette A, Benzinger T, Morris JC, Bateman RJ, Poirier J, Breitner JC, Villeneuve S, The DIAN Study Group, PREVENT-AD Research Group. (2018) Genetic and environmental factors are differentially related to Aβ burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer’s disease. Alzheimer’s Association International Conference. Chicago, USA. * Prize; Oral Presentation [PDF]
  • Pichet Binette A, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S PREVENT-AD Research Group. (2018) Neuropsychiatric burden is related to increased amyloid but not tau deposition in late-middle-aged cognitively normal individuals with a family history of Alzheimer’s disease. Alzheimer’s Association International Conference. Chicago, USA. Oral Presentation [PDF]
  • Pichet Binette A, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S, Prevent-AD Research Group. (2018) Personality traits and neuropsychiatric factors are related to increased amyloid deposition in cognitively normal older adults. Human Amyloid Imaging. Miami, USA.
  • Gonneaud J*, Bedetti C, Pichet Binette A, Benzinger T, Morris R, Bateman R, Poirier J, Breitner JC, Villeneuve S, DIAN Study Group, Prevent-AD Research Group. (2018) Genetic and environmental factors are differentially related to Aβ burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer’s disease. Human Amyloid Imaging. Miami, USA. * Prize; Oral Presentation
  • Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg TO, Schöll M, Danserau C, Villeneuve S, van der Flier W, Scheltens P, Bellec P, Evans A, Hansson O, Ossenkoppele R. (2018) Data-driven tau-PET covariance networks enhance associations with cognition in Alzheimer’s disease. Human Amyloid Imaging Conference. Miami, USA. Oral Presentation

2017

  • Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Poirier J, Rosa-Neto P, Fagan AM, Bateman RJ, Morris JC, Benzinger TL, Johnson SC, Breitner JC, for the Prevent-AD group. (2017) Years to parental onset predicts amyloid burden in healthy elderly with a parental history of sporadic Alzheimer disease. Alzheimer’s Association International Conference. London, UK.
  • Pichet Binette A, Vachon-Presseau E, La Joie E, Poirier J, Rosa-Neto P, Collins L, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2017) Moving away from single AD-signature ROI: Assessing the relationship between whole-brain gray matter pattern, AD pathology, and cognition in healthy elderly at risk of AD. Alzheimer’s Association International Conference. London, UK. [PDF]
  • Vachon-Presseau E, Meyer P-F, Pichet Binette A, Rosa-Neto P, Poirier J, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2017) Assessing the impact of inflammation on limbic circuitry and its role in depression in older adults. Alzheimer’s Association International Conference. London, UK. [PDF]
  • Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JC, Villeneuve S on behalf of the PREVENT-AD Research Group. (2017) Subjective cognitive decline is associated with altered posterior cingulate connectivity in elderly with a familial history of Alzheimer’s Disease. Alzheimer’s Association International Conference. London, UK. Oral Presentation
  • Villeneuve S, Vogel JW, Gonneaud J, Poirier J, Rosa-Neto P, Fagan AM, Bateman RJ, Morris JC, Pichet Binette A, Benzinger TL, Johnson SC, Breitner JC, PREVENT-AD Research Group. (2017) Years to Parental Symptom Onset Predicts Amyloid Burden in Healthy Elderly with a Parental History of Sporadic Alzheimer Disease. Alzheimer’s Association International Conference. London, UK. [PDF]
  • Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg O, Schöll O, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R. (2017) Data-driven tau-pet covariance networks enhance prediction of retrospective cognitive change in Alzheimer’s disease. Alzheimer’s Association International Conference. London, UK. [PDF]
  • Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Fagan AM, Bateman RJ, Morris JC, Benzinger TL, Johnson SC, Poirier J, Breitner JC, for the Prevent-AD group. (2017) Years to parental symptom onset predicts amyloid burden, neurodegeneration and resting state connectivity changes in healthy elderly with a parental history of Alzheimer’s disease. Human Amyloid Imaging Conference. Miami, USA.

2016

  • Pichet Binette A, Vogel JW, Fonov V, Tremblay-Mercier J, Madjar C, Breitner J, Collins L, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2016) High CSF tau is related to reduced hippocampal volume and subjective cognitive decline in healthy elderly with amyloid pathology. Alzheimer’s Association International Conference. Toronto, Canada. [PDF]
  • Vogel JW, Orban P, Pichet Binette A, La Joie R, Savard M, Tam A, Breitner J, Bellec P, Villeneuve S, PREVENT-AD. (2016) Regional Gray Matter Volume and Default Mode Network Connectivity are Associated with Age Relative to Parental Symptom Onset in Sporadic Alzheimer’s Disease. Toronto, Canada. Oral Presentation  [PDF]